Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: Results from an Italian prospective observational study in patients with von Willebrand disease

Haemophilia

Volumn 19, Issue 1, 2013, Pages 82-88

  Castaman, G ^a   Coppola, A ^b   Zanon, E ^c   Boeri, E ^d   Musso, M ^e   Siragusa, S ^f   Federici, A B ^g   Mancuso, G ^h   Barillari, G ⁱ   Biasoli, C ^j   Feola, G ^k   Franchini, M ^l   Moratelli, S ^m   Gamba, G ⁿ   Schinco, P ^o   Valdre L ^p   Dragani, A ^q   Mazzucconi, G ^r   Tagliaferri, A ^s   Morfini, M ^t  

^a SAN BORTOLO HOSPITAL   (Italy)

^b FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d G GASLINI INSTITUTE   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f UNIVERSITY OF PALERMO   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h Children Hospital   (Italy)

ⁱ UNIVERSITY HOSPITAL OF UDINE   (Italy)

^j BUFALINI HOSPITAL   (Italy)

^k San Luca Hospital   (Italy)

^l UNIVERSITY HOSPITAL OF VERONA   (Italy)

^m UNIVERSITY HOSPITAL OF FERRARA   (Italy)

ⁿ FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^o MOLINETTE HOSPITAL   (Italy)

^p UNIVERSITY OF BOLOGNA   (Italy)

^q SPIRITO SANTO HOSPITAL   (Italy)

^r POLICLINICO UMBERTO I   (Italy)

^s UNIVERSITY HOSPITAL OF PARMA   (Italy)

^t CAREGGI UNIVERSITY HOSPITAL   (Italy)

more..

Author keywords

Formulation switch; Haemate P; Observational study; Pasteurized VWF FVIII concentrate; Volume reduced infusion; Von Willebrand disease

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT VON WILLEBRAND FACTOR;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PHARMACOECONOMICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT RESPONSE; VON WILLEBRAND DISEASE;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; BLOOD LOSS, SURGICAL; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; DRUG SUBSTITUTION; FACTOR VIII; FEMALE; HEMORRHAGE; HOSPITALIZATION; HUMANS; ITALY; MALE; MIDDLE AGED; PASTEURIZATION; PROSPECTIVE STUDIES; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84870994167     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12005     Document Type: Article

References (30)

1. Federici AB, Castaman G, Mannucci PM, for the Italian Association of HemophiliaCenters (AICE). Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002;8: 607-21.
2. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004; 351: 683-94.
3. Castaman G, Federici AB, Rodeghiero F, Mannucci PM. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 2003; 88: 94-108.
4. Mannucci PM, Franchini M, Castaman G, Federici AB, Italian Association of Hemophilia Centers. Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus 2009; 7: 117-26.
5. Franchini M. Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage. Blood Transfus 2008; 6(SUPPL 2): S33-8.
6. Schramm W. Haemate P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience. Haemophilia 2008; 14(SUPPL 5): 3-10.
7. Berntorp E. Haemate P/Humate-P: a systematic review. Thromb Res 2009; 124(SUPPL 1): S11-4.
8. ® P. Available online from URL: http://www.cslbehring.it/docs/229/203/RCP_Haemate%20P, 0.pdf. Accessed January 21, 2012.
9. ® P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. Haematologica 2007; 92: 944-51.
10. Tosetto A, Rodeghiero F, Castaman G et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 766-73.
11. EMA Guideline on the clinical investigation of human plasma derived von Willebrand factor products (CPMP/BPWG/220/02), available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500067126.pdf. Accessed July 10, 2012.
12. Morfini M, Coppola A, Zanon E et al. Interim analysis of a prospective observational study on Italian VWD patient, monitoring efficacy and safety during a formulation switch of a pasteurized FVIII/VWF concentrate. J Thromb Haemost 2009; 7(SUPPL 2). abstract n. PP-TH-622.
13. Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002; 87: 224-30.
14. Franchini M, Rossetti G, Tagliaferri A et al. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease. Haematologica 2003; 88: 1279-83.
15. Cox Gill J, Ewenstein BM, Thompson AR et al. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia 2003; 9: 688-95.
16. Thompson AR, Gill JC, Ewenstein BM et al. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P). Haemophilia 2004; 10: 42-51.
17. Lethagen S, Kyrle PA, Castaman G et al. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicentre trial in elective surgery. J Thromb Haemost 2007; 5: 1420-30.
18. Dunkley S, Baker RI, Pidcock M et al. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study. Haemophilia 2010; 16: 615-24.
19. ® in children with von Willebrand disorder: a multicentre retrospective review. Haemophilia 2011; 17: 463-9.
20. ®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery. Thromb Haemost 2011; 105: 1072-9.
21. Halimeh S, Krümpel A, Rott H et al. Long-term secondary prophylaxis in children, adolescents and young adults with von Willebrand disease Results of a cohort study. Thromb Haemost 2011; 105: 597-604.
22. Oldenburg J. Prophylaxis in bleeding disorders. Thromb Res 2011; 127(SUPPL 1): S14-7.
23. Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005; 16: S23-6.
24. Berntorp E. Prophylaxis in von Willebrand disease. Haemophilia 2008; 14(SUPPL 5): 47-53.
25. Federici AB, Gianniello F, Canciani MT, Mannucci PM. Secondary long-term prophylaxis in severe patients with von Willebrand's disease: an Italian cohort study. Blood 2005; 106: 507a., abstract 1782.
26. Federici AB. Prophylaxis of bleeding episodes in patients with von Willebrand's disease. Blood Transfus 2008; 6(SUPPL 2): s26-32.
27. Lethagen S. Clinical experience of prophylactic treatment in von Willebrand disease. Thromb Res 2006; 118(SUPPL 1): S9-11.
28. Schrijvers LH, Beijlevelt-van der Zande M, Peters M, Schuurmans MJ, Fischer K. Learning intravenous infusion in haemophilia: experience from the Netherlands. Haemophilia 2012; 18: 516-20.
29. Colvin BT, Astermark J, Fischer K et al. Inter Disciplinary Working Group. European principles of haemophilia care. Haemophilia 2008; 14: 361-74.
30. De Wee EM, Mauser-Bunschoten EP, Van der Bom JG et al. Health-related quality of life among adult patients with moderate and severe von Willebrand disease. J Thromb Haemost 2010; 8: 1492-9.